Seratrodast (CAS 112665-43-7) Suppliers and Product Information

Seratrodast is a novel benzoquinone derivative and the first thromboxane A2 (TxA2) receptor antagonist to reach the market. It is orally active for the treatment of bronchospastic disorders such as asthma. Seratrodast potently inhibits platelet aggregation and bronchoconstriction induced by a TxA2 mimic and various spasmogenic prostanoids. It shows excellent efficacy in asthma and has potential use in hyper-responsive disorders.

Chemical Properties: Pale Orange Solid

Biological Activity: Thromboxane A2 (TP) receptor antagonist, Antiasthmatic agent, inhibits platelet aggregation and bronchoconstriction induced by a TXA2 mimetic in guinea pigs in vitro.

Frequently Asked Questions about Seratrodast

Q: What is the primary use of Seratrodast?

A: Seratrodast is primarily used as an antiasthmatic agent. It acts as a thromboxane A2 receptor antagonist, helping to treat bronchospastic disorders such as asthma.

Q: How does Seratrodast work?

A: Seratrodast works by inhibiting the effects of thromboxane A2, a metabolite involved in cardiovascular and respiratory diseases. It potently inhibits platelet aggregation and bronchoconstriction induced by TxA2 mimics and other spasmogenic prostanoids.

Q: What forms is Seratrodast available in?

A: Seratrodast is typically available as a pale orange to yellow solid. It is supplied in various package sizes, ranging from 1kg to bulk quantities, depending on the supplier.

Q: Are there any specific storage requirements for Seratrodast?

A: Seratrodast should be stored sealed in dry conditions. It is recommended to store it in a freezer under -20°C for optimal preservation.